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Introduction {#sec1}
============

Cytokines secreted at the site of infection crucially contribute to protective immunity against gastro-intestinal helminth infections ([@bib3], [@bib11]). These cytokines induce diverse local effector functions that range from enhanced migration and turnover of intestinal epithelial cells (IECs), enhanced smooth muscle contractility, and local goblet cell hyperplasia to the induction of effector molecules such as the resistin-like molecules RELM alpha and beta or the *de novo* expression of the mucin Muc5ac, which has a direct detrimental effect on nematode vitality ([@bib3], [@bib14]). Which specific effector functions mediate pathogen-specific host resistance is dependent on the type of parasite, the physical location of the parasite within the gastro-intestinal tract, and the stage of infection ([@bib3]).

Cells at the site of infection that produce cytokines may be part of the innate immune system, such as type-2 innate lymphoid cells (ILC2), as well as of the adaptive immune system, such as pathogen-specific type-2 helper T cells (Th2 cells). ILC2, resident within mucosal tissues, can rapidly secrete cytokines upon exposure to interleukin-33 (IL-33) in an antigen-independent manner and, as demonstrated by adoptive transfer of *in*-*vitro*-expanded ILC2, can directly contribute to host resistance ([@bib24], [@bib25], [@bib31]). By contrast, pathogen-specific Th2 cells need first to be primed in an antigen-dependent manner, clonally expand, and migrate to the site of infection before they can contribute to nematode expulsion. Nevertheless, during gastro-intestinal helminth infections, Th2 cells rapidly outnumber ILC2 at the site of infection ([@bib13]), and a number of publications suggest that these Th2 cells directly contribute to pathogen clearance ([@bib2], [@bib35], [@bib37]).

Although cytokine production by T cells is closely controlled by antigen-dependent T cell receptor (TCR) activation ([@bib32]), it has recently been shown that Th2 cells can directly contribute to host resistance in a TCR-independent manner, by secreting the type-2 effector cytokine IL-13 upon exposure to IL-33 ([@bib13], [@bib12]). This antigen-independent potential of Th2 cells to produce cytokines raises the question to which extent both antigen-dependent and -independent Th2 cell effector functions contribute to host resistance and whether these two functions are integrated.

We have shown before that activated effector CD4 T cells express the epidermal growth factor receptor (EGFR) ([@bib38]). Here, we demonstrate that EGFR expression on Th2 cells was of critical importance for host resistance during gastro-intestinal helminth infections. Only following the induction of EGFR expression and the amphiregulin (AREG)-dependent formation of a functional signaling complex between the EGFR and T1/ST2 (the IL-33R) could activated Th2 cells secrete IL-13 in an antigen-independent way upon exposure to IL-33. EGFR expression by Th2 cells was induced by antigen-mediated activation. Thus, via the expression of the EGFR, TCR-mediated activation licenses Th2 cells to respond in an innate-like fashion, while at the same time controlling the overall immune response in an antigen-specific manner.

Results {#sec2}
=======

EGFR Expression by Activated Th2 Cells Contributes to Host Resistance {#sec2.1}
---------------------------------------------------------------------

Since CD4^+^ effector T cells can express the EGFR ([@bib17], [@bib38]), we explored whether Th2 cells might express the EGFR during helminth infections and whether EGFR expression contributes to host resistance. While we found negligible EGFR expression on CD4^+^ T cells from uninfected mice, EGFR expression was upregulated on CD4^+^ T cells derived from the duodena ([Figure 1](#fig1){ref-type="fig"}A) and mesenteric lymph nodes (mLN) ([Figure 1](#fig1){ref-type="fig"}B) of mice infected with the gastro-intestinal helminth *Heligmosomoides polygyrus*. EGFR expression was restricted to recently activated CD4^+^ T cells, as defined by the co-expression of the activation marker CD69 ([Figure 1](#fig1){ref-type="fig"}B). In contrast to mLN, the frequency of EGFR positive CD4^+^ T cells in the spleen was lower ([Figure 1](#fig1){ref-type="fig"}C), although a comparable fraction of CD4^+^ T cells expressed the Th2 transcription factor GATA3 in both lymphoid organs ([Figure 1](#fig1){ref-type="fig"}D).Figure 1EGFR Expression by T Cells Contributes to Host Resistance against Gastro-intestinal Helminth Infections(A--C) WT, *Egfr*^*fl/fl*^, and *Egfr*^*fl/fl*^*xCd4-cre* (EGFR^ΔCD4^) mice were infected with *H. polygyrus* or *N. brasiliensis* or left untreated. Percentage and absolute number of EGFR expressing CD4^+^ T helper cells in (A) duodena, (B) mLN, and (C) spleen, and EGFR expression on total CD4^+^ and CD69^+^ and CD69^--^ mLN-derived T cells from naive or *H. polygyrus*-infected mice was determined by flow cytometry analysis on day 14 post infection.(D) Comparison of GATA3 expression on CD4^+^ T cells from mLN and spleen of *H. polygyrus*-infected *Egfr*^*fl/fl*^ and EGFR^ΔCD4^ mice.(E) Time-dependent egg load in feces and worm burden 4 weeks post infection with *H. polygyrus* (n = 4 mice).(F) Time-dependent egg load in feces and worm burden 9 days post infection with *N. brasiliensis* (n = 3 mice).All data are representative of at least two independent experiments (mean ± SEM); results for individual mice are shown as dots. See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"}.

To determine the physiological relevance of EGFR expression on T cells, we generated a mouse strain that lacks EGFR expression in T cells by crossing *Cd4-cre* mice onto an *Egfr*^fl/fl^ background. Uninfected *Egfr*^fl/fl^x*Cd4-cre* mice showed no signs of immune dysregulation, and T cell development appeared normal ([@bib38]; [Figure S1](#mmc1){ref-type="supplementary-material"}). However, *Egfr*^fl/fl^x*Cd4-cre* mice infected with the gastro-intestinal helminth *H. polygyrus* showed significantly higher egg burdens and worm clearance was delayed significantly in comparison to infected wild-type (WT) control mice ([Figure 1](#fig1){ref-type="fig"}E). Similar results were obtained when *Egfr*^fl/fl^x*Cd4-cre* mice were infected with *Nippostrongylus brasiliensis*, another gastro-intestinal nematode ([Figure 1](#fig1){ref-type="fig"}F).

Immunity to gastro-intestinal helminth infections is closely related to the expansion and function of regulatory T (Treg) cells ([@bib1], [@bib33]). Since Treg cell function is closely regulated by EGFR expression ([@bib26], [@bib27], [@bib38]), we rationalized that Treg cell dysfunction may explain the enhanced susceptibility of *Egfr*^fl/fl^x*Cd4-cre* mice to helminth infection. However, mice with a Treg cell-specific EGFR deficiency (*Foxp3-cre x Egfr*^*fl/fl*^) cleared *H. polygyrus* as efficiently as WT control mice ([Figure S2](#mmc1){ref-type="supplementary-material"}), suggesting that EGFR expression on Treg cells did not contribute to the enhanced susceptibility of *Egfr*^*fl/fl*^*xCd4-cre* mice.

In order to determine the cause for the enhanced susceptibility of *Egfr*^*fl/fl*^*xCd4-cre* mice to helminth infections, we analyzed the immune response of WT and *Egfr*^*fl/fl*^*xCd4-cre* mice to *H. polygyrus* infection in more detail ([Figure S3](#mmc1){ref-type="supplementary-material"}). We observed that percentages of CD4^+^ T cells and their ability to produce IL-13 upon *in vitro* re-stimulation were comparable in both strains ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Pathogen-specific antibody titers within the serum and faeces were unaffected by a lack of EGFR expression on T cells ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Furthermore, we found similar frequencies of ILC2 in the mLN of infected *Egfr*^*fl/fl*^*xCd4-cre* and WT control mice, and their capacity to produce type-2 cytokines upon IL-33 exposure was unaffected ([Figure S3](#mmc1){ref-type="supplementary-material"}D), indicating that a lack of EGFR expression on T cells does not fundamentally affect ILC2 expansion and function. Furthermore, *in*-*vitro*-generated Th2 cells from *Egfr*^*fl/fl*^*xCd4-cre* and WT mice expressed type-2-specific transcription factors GATA-3, c-MAF, and STAT-6 ([Figure S3](#mmc1){ref-type="supplementary-material"}E), showed no major transcriptional deviations from each other ([Figure S3](#mmc1){ref-type="supplementary-material"}E), and expanded similarly ([Figure S3](#mmc1){ref-type="supplementary-material"}E).

From these data we conclude that EGFR expression on CD4^+^ T cells is critical for Th2 cell-mediated host resistance to gastro-intestinal helminth infections. Nevertheless, a lack of EGFR expression does not induce a fundamental dysfunction of Th2 cells.

IL-13 Production at the Site of Infection Is Dependent on EGFR Expression by T Cells {#sec2.2}
------------------------------------------------------------------------------------

One central component of host resistance against helminth infections is the expression of the effector cytokine IL-13 ([@bib13], [@bib20]). *H. polygyrus* larvae are particularly sensitive to IL-13-induced effector mechanism from day 7 until day 9 post infection, when they leave the gut mucosa in order to reside in the intestinal lumen ([@bib30]). We therefore determined cytokine production at the site of infection during this stage of infection. We found that *Il13* mRNA expression in the duodenum was significantly lower in infected *Egfr*^*fl/fl*^*xCd4-cre* mice in comparison to WT mice ([Figure 2](#fig2){ref-type="fig"}A). This deficiency in cytokine expression was specific for IL-13, since the expression of *Il5* and *Il4* mRNA ([Figure 2](#fig2){ref-type="fig"}A) and the influx of T cells into the duodenum ([Figure 2](#fig2){ref-type="fig"}A) were unaffected. In contrast to the site of infection, *Il13* mRNA expression within the draining mLN was similar in both mouse strains ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Strikingly, the diminished message for *Il13* in the duodena of *Egfr*^*fl/fl*^*xCd4-cre* mice directly correlated with a lack of Muc5ac expression ([Figure 2](#fig2){ref-type="fig"}B), an IL-13-induced mucin that directly affects gastro-intestinal nematode vitality ([@bib14]).Figure 2IL-13 Production at the Site of Infection Is Dependent on EGFR Expression by T CellsWT, *Egfr*^*fl/fl*^, and *Egfr*^*fl/fl*^*xCd4-cre* (EGFR^ΔCD4^) mice were infected with *H. polygyrus* or left untreated.(A--C) At day 8 post infection (A) *Il13*, *Il5, Il4, Cd3e*, and (B) *Muc5ac* mRNA was analyzed in the duodena by RT-PCR. (C) Mice were treated with BFA 6 hr prior to harvest, after which, single-cell suspensions from duodena of naive or infected mice were prepared and analyzed by flow cytometry: percentage and absolute number of IL-13-expressing T cells (left) and ILC2 (right).(D) *H. polygyrus*-infected EGFR^ΔCD4^ mice received either PBS or IL-13 at days 6, 7, and 8 post infection, and egg counts were analyzed 2 weeks later.(E) Flow cytometry-sorted mLN-derived CD4^+^ T cells were transferred from naive or *H. polygyrus*-infected *Egfr*^*fl/fl*^ or EGFR^ΔCD4^ mice into infected (day 7 post infection) recipient *Il13*^*−/−*^ mice, and eggs were counted in feces 2 weeks later; egg load on a WT strain is shown for reference.(F) mLN-derived CD4^+^ T cells were transferred from naive or *H. polygyrus*-infected *Egfr*^*fl/fl*^ or EGFR^ΔCD4^ mice into infected (day 7 post infection) recipient EGFR^ΔCD4^ mice, and eggs were counted in feces 2 weeks later.All data are representative of at least two independent experiments (mean ± SEM); results for individual mice are shown as dots. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

In order to determine the cellular source of IL-13 at the site of infection, we injected brefeldin A into mice infected with *H. polygyrus*, at day 7 post infection. We harvested the duodenum 6 hr later and purified intestine-residential leukocytes in the presence of monensin. Since brefeldin A and monensin prevent the secretion of cytokines, this approach allowed us to directly reveal which cells expressed effector cytokines within the duodenum of infected mice. As shown in [Figure 2](#fig2){ref-type="fig"}C, CD4^+^ T cells but not ILC2 expressed detectable amounts of IL-13 at this stage of infection. In addition, only CD4^+^ T cells in infected WT but not in *Egfr*^*fl/fl*^*xCd4-cre* mice expressed IL-13, while CD4^+^ T cells from both mouse strains expressed similar amounts of IL-5 ([Figures 2](#fig2){ref-type="fig"}C, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). Also, the numbers of CD4^+^ T cells and ILC2 recovered from the infected duodena were comparable for both mouse strains ([Figure S4](#mmc1){ref-type="supplementary-material"}D).

To confirm that a lack of IL-13 expression could be the cause of diminished worm clearance, we injected rIL-13 into *Egfr*^*fl/fl*^*xCd4-cre* mice at days 6, 7, and 8 post infection. Supplementation of IL-13 at this stage of infection resulted in significantly lower egg counts and worm burdens in infected *Egfr*^*fl/fl*^*xCd4-cre* mice, fully reverting their susceptible phenotype ([Figure 2](#fig2){ref-type="fig"}D). Furthermore, the transfer of CD4^+^ T cells derived from infected WT but not from *Egfr*^*fl/fl*^*xCd4-cre* donors restored host resistance of IL-13-deficient mice to *H. polygyrus* infections ([Figure 2](#fig2){ref-type="fig"}E). Similarly, transfer of purified CD4^+^ T cells from *H. polygyrus*-infected WT donors into infected *Egfr*^*fl/fl*^*xCd4-cre* mice significantly diminished egg output in *Egfr*^*fl/fl*^*xCd4-cre* recipient mice ([Figure 2](#fig2){ref-type="fig"}F), whereas transfer of purified CD4^+^ T cells from *Egfr*^*fl/fl*^*xCd4-cre* donors did not.

Taken together, our data show that a lack of EGFR expression on T cells leads to diminished T cell-derived IL-13 expression in the duodenum at the time point when *H. polygyrus* worms establish themselves in the gut lumen. Diminished IL-13 expression at this stage of infection correlated with diminished Muc5ac expression and a defect in worm clearance, while application of recombinant IL-13 or transfer of CD4^+^ T cells from infected WT mice was sufficient to restore worm clearance. Consequently, the lack of IL-13 expression by CD4^+^ T cells at the site of infection is likely to be causative for the enhanced susceptibility of *Egfr*^*fl/fl*^*xCd4-cre* mice to *H. polygyrus* infection.

IL-33-Induced IL-13 Production by Th2 Cells Is Dependent on EGFR Expression {#sec2.3}
---------------------------------------------------------------------------

IL-13 expression by Th2 cells can either be induced by TCR activation or in an antigen-independent way by exposure to IL-33 ([@bib12]). In order to determine whether a lack of responsiveness to IL-33 by Th2 cells explained the diminished IL-13 expression in *Egfr*^*fl/fl*^*xCd4-cre* mice, we determined IL-13 expression by CD4^+^ T cells derived from mice infected with *H. polygyrus ex vivo.* Despite similar expression of the IL-33 receptor T1/ST2 ([Figure 3](#fig3){ref-type="fig"}A), CD4^+^ T cells derived from *H. polygyrus*-infected *Egfr*^*fl/fl*^*xCd4-cre* mice failed to express IL-13 upon exposure to IL-33. However, IL-33-induced IL-5 and IL-13 expression upon anti-CD3 stimulation was unaffected ([Figure 3](#fig3){ref-type="fig"}B). These data demonstrate that Th2 cells of *Egfr*^*fl/fl*^*xCd4-cre* mice are capable of producing IL-13 upon antigen-specific stimulation but fail to produce IL-13 in response to IL-33.Figure 3IL-33-Induced IL-13 Production by Th2 Cells Is Dependent on EGFR ExpressionWT, *Egfr*^fl/fl^, and *Egfr*^*fl/fl*^*xCd4-cre* (EGFR^ΔCD4^) mice were infected with *H. polygyrus*, and on day 14 post infection, mLN were harvested.(A) Comparison of T1/ST2 expression on mLN CD4^+^ T cells from *H. polygyrus*-infected *Egfr*^*fl/fl*^ and EGFR^ΔCD4^ mice.(B) mLN cells were stimulated with rIL-33, anti-CD3, or media only, and expression of IL-13 and IL-5 was determined by intra-cellular cytokine staining and flow cytometry analysis.(C) mLN CD4^+^ T cells from *H. polygyrus*-infected WT mice were flow cytometry-sorted based on T1/ST2 and/or EGFR expression, and T cell populations were stimulated with rIL-33 for 4 hr. Subsequently, *Il13* and *Il5* mRNA was analyzed by RT-PCR.(D) MHCII-deficient mice were infected with *H. polygyrus* and 7 days post infection received CD4^+^ T cells derived from mLN of naive or *H. polygyrus*-infected WT or EGFR^ΔCD4^ mice. Worm burden and egg counts were determined 2 weeks post infection.(E--G) MHCII-deficient mice were infected with *N. brasiliensis* and simultaneously received CD4^+^ T cells from mLN of naive (WT) or *H. polygyrus*-infected WT, EGFR^ΔCD4^, or T1/ST2-deficient mice, collected 2 weeks after infection. At day 6 post transfer, worm burden and eggs counts (E) were determined, IL-13 and IL-5 (F) expression in BAL was evaluated by ELISA, and expression of Ym1 in alveolar macrophages and total number of eosinophils in the BAL (G) were analyzed by flow cytometry.Data are representative of two independent experiments (mean ± SEM); results for individual mice are shown as dots.

To determine whether there might be a link between EGFR and T1/ST2 expression, we flow cytometry-sorted activated CD4^+^ T cells (CD69^+^) derived from the mLN of *H. polygyrus*-infected mice based on T1/ST2 and/or EGFR expression. As shown in [Figure 3](#fig3){ref-type="fig"}C, the induction of IL-13 in response to IL-33 exposure was restricted to the double-positive population, whereas IL-5 induction was dependent on T1/ST2 expression only. These findings demonstrate that T1/ST2-expressing Th2 cells require EGFR expression in order to produce IL-13 upon IL-33 exposure.

To address whether the previously described TCR-independent and IL-33-dependent capacity of Th2 cells to contribute to host resistance to helminth infections ([@bib13]) requires EGFR expression, we transferred mLN-derived CD4 T cells from *H. polygyrus*-infected *Egfr*^*fl/fl*^*xCd4-cre* or WT mice into *H. polygyrus*-infected major histocompatibility complex (MHC)-II-deficient mice, at day 7 post infection. While transfer of WT cells significantly diminished worm burden, transfer of cells derived from infected *Egfr*^*fl/fl*^*xCd4-cre* mice did not ([Figure 3](#fig3){ref-type="fig"}D). Thus, the innate capacity of Th2 cells to contribute to worm expulsion is directly dependent on EGFR expression.

Furthermore, we decided to determine how the expression of EGFR on Th2 cells influences their innate-like cytokine expression within secondary inflamed tissues. To this end, we transferred purified CD4^+^ T cell derived from the mLN of *H. polygyrus*-infected mice into *N. brasiliensis*-infected MHC-II-deficient mice. While *H. polygyrus* exclusively infects the gastro-intestinal tract, *N. brasiliensis* larvae migrate through the lung on route to intestine colonization, leaving behind a strong inflammatory environment. Transfer of purified CD4^+^ T cells derived from *H. polygyrus*-infected WT mice into *N. brasiliensis*-infected MHC-II-deficient mice led to a significant reduction in worm burdens ([Figure 3](#fig3){ref-type="fig"}E). In contrast, transfer of CD4^+^ T cells from infected *Egfr*^*fl/fl*^*xCd4-cre* or T1/ST2-deficient mice did not ([Figure 3](#fig3){ref-type="fig"}E).

Of note, *N. brasiliensis*-infected MHC-II-deficient mice that had received CD4^+^ T cells derived from *H. polygyrus*-infected WT mice showed significantly elevated IL-13 and IL-5 expression in the bronchoalveolar lavage (BAL) ([Figure 3](#fig3){ref-type="fig"}F). In contrast, MHC-II-deficient mice that had received CD4^+^ T cells derived from *Egfr*^*fl/fl*^*xCd4-cre* mice showed elevated IL-5 but lower IL-13 expression ([Figure 3](#fig3){ref-type="fig"}F). MHC-II-deficient mice that had received CD4^+^ T cells derived from *H. polygyrus*-infected T1/ST2-deficient mice lacked detectable quantities of either cytokine ([Figure 3](#fig3){ref-type="fig"}F). Consistent with these cytokine expression profiles, alveolar macrophages from mice that received WT CD4^+^ T cells showed enhanced expression of Ym1 ([Figure 3](#fig3){ref-type="fig"}G), a marker of alternative activation of macrophages that can be induced through IL-13 signaling via the IL-4Rα chain. However, mice that received either T1/ST2-deficient or EGFR-deficient CD4^+^ T cells failed to induce alternative activation of alveolar macrophages ([Figure 3](#fig3){ref-type="fig"}G). In contrast to macrophage skewing, expansion of eosinophils in the BAL of *N. brasiliensis*-infected MHC-II-gene-deficient mice, a process dependent on IL-5 expression, was enhanced in mice that received WT or EGFR-deficient CD4^+^ T cells but was absent in mice that received T1/ST2-deficient CD4^+^ T cells ([Figure 3](#fig3){ref-type="fig"}G).

Taken together, our data demonstrate that EGFR expression by Th2 cells regulates their antigen-independent cytokine expression in response to IL-33.

Induced EGFR Expression Licenses Th2 Cells to Express IL-13 in an Innate-like Way {#sec2.4}
---------------------------------------------------------------------------------

Next, we wanted to determine which factors influence EGFR expression on Th2 cells. In contrast to Th2 cells derived from the duodenum and mLN of infected mice, Th2 cells derived from the spleen of *H. polygyrus*-infected mice had lower EGFR expression ([Figure 1](#fig1){ref-type="fig"}A--1C). We therefore used splenic CD4^+^ T cells from *H. polygyrus*-infected mice to determine which stimuli induce EGFR expression on CD4^+^ T cells. We stimulated these cells overnight with either cytokines or via the TCR, using antigen-specific stimulation or activating anti-CD3 antibody. Stimulation through the TCR induced EGFR expression in CD4^+^ T cells ([Figure 4](#fig4){ref-type="fig"}A). In addition, as described before ([@bib17]), exposure to cytokines that induce STAT5 signaling, such as IL-2, IL-7, or TSLP, also induced EGFR expression in CD4^+^ T cells; however, exposure to IL-33 did not ([Figure 4](#fig4){ref-type="fig"}A). In accordance with EGFR expression, overnight exposure to TSLP, a cytokine expressed at sites of helminth infection ([@bib34]), restored the capability of WT but not *Egfr*^*fl/fl*^*xCd4-cre* splenic T cells from *H. polygyrus*-infected mice to produce IL-13 in response to IL-33 ([Figure 4](#fig4){ref-type="fig"}A), demonstrating that induced EGFR expression licenses Th2 cells to produce IL-13 upon exposure to IL-33.Figure 4Transient EGFR Expression Licenses Th2 Cells to Express IL-13 in Response to IL-33(A) Splenocytes were isolated from *H. polygyrus*-infected WT and *Egfr*^*fl/fl*^*xCd4-cre* (EGFR^ΔCD4^) mice, and expression of EGFR on T cells was determined by flow cytometry analysis after overnight incubation with *H. polygyrus* excretory-secretory products (HES), adult worm extract (HEX), anti-CD3, vehicle (C), rIL-7, rIL-2, rTSLP, or rIL-33 (upper). Alternatively (lower), splenocytes were stimulated overnight with rTSLP, and subsequently, IL-13 expression by T cells was analyzed by intra-cellular cytokine staining and flow cytometry analysis following re-stimulation with rIL-33 or anti-CD3 antibody.(B) Ly5.2^+^ WT mice were infected with *H. polygyrus*, and 2 weeks after infection, mLN cells were transferred into naive Ly5.1^+^ hosts. Spleens of recipient mice were harvested after 0--3.5 days post transfer, and the expression of EGFR (upper) and T1/ST2 (lower) on transferred Ly5.2^+^ CD4^+^ T cells was determined by flow cytometry analysis. Expression of IL-13 (upper) and IL-5 (lower) upon exposure to rIL-33 was determined by intra-cellular cytokine expression and flow cytometry analysis (n = 3 mice).(C) WT *H. polygyrus*-infected mice were treated with pyrantel embonate, and mLN were harvested after 0--6 days post treatment. EGFR (upper) and T1/ST2 (lower) expression on CD4^+^ T cells was determined by flow cytometry, and expression of IL-13 (upper) and IL-5 (lower) upon exposure to IL-33 was determined by intra-cellular cytokine staining and flow cytometry analysis (n = 3 mice).Data are representative of at least two independent experiments (mean ± SEM); results for individual mice are shown as dots. Data in (B) and (C) are presented as percentage of expression on day 0.

In addition to the induction of EGFR expression, we also wanted to know for how long Th2 cells remain responsive to IL-33 and whether this sensitivity would correlate with EGFR expression. While T1/ST2 expression on activated Th2 cells is known to be stable ([@bib19]), the duration of EGFR expression on activated Th2 cells remains unknown. To address EGFR stability, we transferred activated Th2 cells from *H. polygyrus*-infected WT mice into naive mice ([Figure 4](#fig4){ref-type="fig"}B) or, alternatively, induced worm clearance by administering a deworming drug ([Figure 4](#fig4){ref-type="fig"}C). As shown in [Figure 4](#fig4){ref-type="fig"}, EGFR expression on activated Th2 cells dropped rapidly upon transfer from infected Ly5.2 mice into uninfected Ly5.1 mice or upon drug-mediated worm expulsion. This drop in EGFR expression directly correlated with a loss of capacity of Th2 cells to produce IL-13 upon IL-33 exposure ([Figures 4](#fig4){ref-type="fig"}B and 4C). In contrast, the capacity of these cells to produce IL-5 upon exposure to IL-33 remained unimpaired, which directly correlated with the unaffected T1/ST2 expression on Th2 cells ([Figures 4](#fig4){ref-type="fig"}B and 4C).

Taken together, these data demonstrate that EGFR expression on Th2 cells is only transient and rapidly lost in the absence of inflammation.

Antigen-Independent Function of Th2 Cells Requires Antigen-Induced EGFR Expression {#sec2.5}
----------------------------------------------------------------------------------

Our data show that cytokines, such as TSLP, can induce EGFR expression in CD4^+^ T cells derived from *H. polygyrus*-infected mice. Therefore, we wanted to determine whether, under physiological conditions, EGFR expression on Th2 cells can be driven by cytokine-induced bystander activation or at one point has to be controlled by antigen presentation. To this end, we compared EGFR expression on mLN-derived CD4^+^ T cells from *H. polygyrus*-infected mice or memory CD4^+^ T cells from drug-treated mice. [Figure 5](#fig5){ref-type="fig"}A shows that, whereas recently activated CD4^+^ T cells increase EGFR expression, memory cells do not. Thus, we sorted memory cells (CD45RB^low^CD25^--^CD44^high^) and activated Th2 cells (CD69^+^ST2^+^) based on EGFR expression ([Figure 5](#fig5){ref-type="fig"}B) and either exposed these cell populations directly to IL-33 or cultured memory and activated EGFR^--^ CD4^+^ T cells in the presence of CD3-stimulating antibodies or TSLP overnight. We observed that EGFR-expressing activated Th2 cells readily expressed IL-13 upon IL-33 exposure, while memory CD4^+^ T cells did not ([Figure 5](#fig5){ref-type="fig"}C). Furthermore, we observed that TCR-mediated activation and TSLP stimulation could induce EGFR expression in the activated cell population that were isolated based on a lack of EGFR expression; however, CD4^+^ T cells within the memory population expressed EGFR only upon TCR-mediated activation, while TSLP alone was insufficient to induce EGFR expression ([Figure 5](#fig5){ref-type="fig"}D). Furthermore, the capability of the different sorted cell populations to express IL-13 in response to IL-33 was directly correlated to EGFR expression ([Figure 5](#fig5){ref-type="fig"}E).Figure 5EGFR Expression on Th2 Cells Is Induced by TCR Activation and Maintained by Cytokines(A--E) WT *H. polygyrus*-infected mice were either treated with pyrantel embonate or left untreated; mLN were collected 14 days after treatment.(A) EGFR expression on activated (CD69^+^, red bars) or memory (CD25^--^CD45RB^low^CD44^hi^, blue bars) CD4^+^ T cells was analyzed by flow cytometry.(B) Activated CD4^+^ T cells were flow cytometry-sorted from infected mice into ST2^+^ EGFR^+^ (red) and ST2^+^ EGFR^--^ (orange) populations. Memory CD4^+^ T cells (CD25^--^CD45RB^low^CD44^hi^) were flow cytometry-sorted from dewormed mice.(C) After sorting, activated EGFR^+^ and memory cells were stimulated with rIL-33 or media only, and expression of IL-13 was determined by flow cytometry analysis.(D--E) Activated EGFR^--^ and memory cells were cultured overnight with rTSLP or anti-CD3 antibodies, and expression of EGFR on CD4^+^ T cells was determined by flow cytometry analysis (D) or were re-stimulated with rIL-33 and expression of IL-13 determined by intra-cellular cytokine staining and flow cytometry analysis (E).(F--G) *Egfr*^*fl/fl*^*xCd4-cre* (EGFR^ΔCD4^) mice were infected with *H. polygyrus* and received either flow cytometry-sorted activated CD4 T cells (red) (F) or flow cytometry-sorted naive or memory T cells (blue) (G) from OVA-challenged mice. Worm burden and egg counts in feces were determined 2 weeks post transfer.Data in (A)--(E) are representative of at least two independent experiments (mean ± SEM); results for individual mice are shown as dots. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

In order to address the *in vivo* relevance of antigen presentation for the re-activation of memory CD4^+^ T cells, we transferred CD4^+^ T cells into MHC-II-deficient mice. Transferred cells were either derived from infected mice or from mice that had been drug-treated 2 weeks prior to transfer. While CD4^+^ T cells from infected mice significantly diminished worm burden, transfer of CD4^+^ T cells from drug-treated mice did not ([Figure S5](#mmc1){ref-type="supplementary-material"}A). However, transfer of CD4^+^ T cells from dewormed WT mice was sufficient to induce worm expulsion in infected *Egfr*^*fl/fl*^*xCd4-cre* recipients ([Figure S5](#mmc1){ref-type="supplementary-material"}B), suggesting that antigen-specific re-activation enabled the transferred resting Th2 cells to contribute to worm expulsion.

In order to exclude possible variations in numbers of transferred T cells, we modified the previous experimental approach and immunized WT and *Egfr*^*fl/fl*^*xCd4-cre* mice with ovalbumin (OVA) and subsequently repeatedly challenged these mice with OVA intra-nasally. We then harvested thoracic lymph nodes and sorted activated T cells immediately after challenge or memory CD4^+^ T cells 4 weeks post challenge, and equal number of memory or activated CD4^+^ T cells were transferred into *H. polygyrus-*infected *Egfr*^*fl/fl*^*xCd4-cre* recipient mice. As shown in [Figure 5](#fig5){ref-type="fig"}F, transfer of activated WT but not *Egfr*^*fl/fl*^*xCd4-cre* CD4^+^ T cells induced worm expulsion. Memory CD4^+^ T cells, however, were not able to provide protection unless recipient mice were immunized with OVA ([Figure 5](#fig5){ref-type="fig"}G), whereby worm expulsion directly correlated with the presence of EGFR-expressing CD4^+^ T cells within the duodenum ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

Taken together, these experiments show that only antigen-specific activation of Th2 cells induces EGFR expression, while cytokines maintain EGFR expression in recently activated Th2 cells.

T1/ST2 and EGFR Form a Common Signaling Complex on Th2 Cells {#sec2.6}
------------------------------------------------------------

Finally, we wanted to determine the mechanism by which EGFR expression controls IL-33-induced cytokine expression. IL-13 expression is critically dependent on ERK activation ([@bib29]), and because MAP-kinase signaling is one of the principal pathways induced by EGFR activation, we hypothesized that EGFR-mediated activation of MAP-kinase signaling may facilitate IL-33 to induce IL-13 expression in Th2 cells. In accordance with this hypothesis, IL-33 failed to induce ERK phosphorylation in EGFR-deficient CD4^+^ T cells ([Figure 6](#fig6){ref-type="fig"}A), and treatment of T cells derived from *H. polygyrus*-infected WT mice with MEK inhibitors, which interfere with the MAP-kinase signaling pathway, phenocopied *Egfr*^*fl/fl*^*xCd4-cre* T cells ([Figure S6](#mmc1){ref-type="supplementary-material"}A). IL-33-induced IL-5 and IL-4 expression ([Figure S6](#mmc1){ref-type="supplementary-material"}B) as well as IκBα degradation ([Figure S6](#mmc1){ref-type="supplementary-material"}B) were unaffected by a lack of EGFR expression. This finding is in accordance with the fact that IL-5 expression is dependent on p38 but not on ERK activation ([@bib9]). Accordingly, IL-33-induced IL-5 expression was unaffected by MEK inhibitor treatment ([Figure S6](#mmc1){ref-type="supplementary-material"}C). These data demonstrate that specifically IL-33-induced ERK activation is EGFR dependent, while other signaling pathways downstream of T1/ST2 are not.Figure 6IL-33-Induced IL-13 Production by Th2 Cells Is Dependent on a Signaling Complex between T1/ST2 and EGFRWT and *Egfr*^*fl/fl*^*xCd4-cre* (EGFR^ΔCD4^) mice were infected with *H. polygyrus* larvae, and on day 14 post infection, mLN were harvested.(A--C) Cells were stimulated with rIL-33, anti-CD3, or media in the presence of gefitinib, marimastat, or vehicle, and p-ERK (A and C) or IL-13 (B) expression was determined by intra-cellular staining and flow cytometry analysis.(D and E) Cells were stimulated with rHB-EGF, anti-CD3, or media, and IL-13 (D) and p-ERK (E) expression was determined by intra-cellular staining and flow cytometry analysis.(F) EGFR expression on stimulated mLN WT CD4^+^ T cells in the presence of monensin was analyzed by flow cytometry.(G) HEK293T cells were transfected as indicated with T1/ST2, the IL-1RacP, or the EGFR alone or in combination. Subsequently, the cells lysates were analyzed for the expression of the transfected proteins (input, left panel). The same lysates were also subjected to an EGFR-specific immunoprecipitation (EGFR-IP, right panel) or were treated with the isotype control (iso, right panel). Precipitates were analyzed by immunoblot.(H) mLN (upper) or HaCaT cells (lower) were stimulated with rIL-33, rHB-EGF, or media, and the EGFR phosphorylation at position Y1068 was determined by intra-cellular staining and flow cytometry analysis (upper) or immunoblot (lower).All data are representative of at least two independent experiments (mean ± SEM); results for individual mice are shown as dots. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

In order to induce EGFR signaling upon IL-33 exposure, T1/ST2 could either form an active signaling complex together with the EGFR, or T1/ST2 could induce the expression or release of EGFR ligands that then indirectly activate the EGFR.

To address these possibilities, we first exposed CD4^+^ T cells derived from *H. polygyrus*-infected mice with IL-33 in the presence of the EGFR inhibitor gefitinib and the pan-metalloprotease inhibitor marimastat, which disrupts the release of newly expressed EGFR ligands from the cell surface. EGFR inhibition prevented IL-33-induced IL-13 production and ERK phosphorylation ([Figures 6](#fig6){ref-type="fig"}B and 6C), while the inhibition of EGFR trans-activation by marimastat had no influence on IL-33-induced IL-13 expression nor on ERK phosphorylation ([Figures 6](#fig6){ref-type="fig"}B and 6C). Furthermore, we observed that the high-affinity EGFR ligand HB-EGF was not able to induce IL-13 expression by CD4^+^ T cells despite inducing ERK activation in these cells ([Figures 6](#fig6){ref-type="fig"}D and 6E), indicating that IL-33-induced IL-13 expression is not mediated by the release of EGFR ligands.

To address whether both receptors may physically interact, we studied the internalization of the EGFR on IL-33-treated CD4^+^ T cells derived from *H. polygyrus*-infected mice in the presence of monensin. Monensin allows for activation-induced internalization of trans-membrane receptors but prevents re-circulation of these receptors back to the cell surface. As shown in [Figure 6](#fig6){ref-type="fig"}F, IL-33 induced the internalization of the EGFR. This activation-induced internalization was specific for IL-33 exposure and not observed upon TCR-mediated stimulation ([Figure 6](#fig6){ref-type="fig"}F). Additionally, EGFR co-immunoprecipitated with T1/ST2 and its associated signaling molecules, such as SOS and Shp-2, when co-expressed in HEK cells ([Figure 6](#fig6){ref-type="fig"}G). Similarly, EGFR co-immunoprecipitated with T1/ST2 from IL-33-treated CD4^+^ T cells derived from *H. polygyrus*-infected WT but not from *Egfr*^*fl/fl*^*xCd4-cre* mice ([Figure S6](#mmc1){ref-type="supplementary-material"}D), further suggesting that both receptors may form a shared complex.

EGFR-induced activation of the MAP-kinase signaling pathway is mediated via the phosphorylation of Tyr-1068. Thus, we wanted to test whether IL-33 may induce Tyr-1068 of the EGFR. As shown in [Figure 6](#fig6){ref-type="fig"}H, IL-33 induced the rapid phosphorylation of Tyr-1068 in CD4^+^ T cells derived from *H. polygyrus*-infected mice ([Figure 6](#fig6){ref-type="fig"}H) as well as in HaCat cells ([Figure 6](#fig6){ref-type="fig"}H).

Based on these data, we conclude that, similar to the reported interaction between T1/ST2 and c-kit on mast cells ([@bib8]), T1/ST2 forms an active signaling complex with the EGFR on Th2 cells, which enables IL-33 to activate the MAP-kinase signaling pathway and induce ERK phosphorylation and consequently IL-13 expression.

Formation of a Common Signaling Complex Is Dependent on Th2 Cell-Derived Amphiregulin {#sec2.7}
-------------------------------------------------------------------------------------

Another important type-2 cytokine and EGF-like growth factor is AREG ([@bib39]). Similar to that of EGFR ([Figure 4](#fig4){ref-type="fig"}A), AREG expression in Th2 cells is also induced by TCR and TSLP, but not IL-33 ([Figure S7](#mmc1){ref-type="supplementary-material"}A). We have shown that Th2 cell-derived AREG enhances the clearance of the gastro-intestinal helminth *Trichuris muris* ([@bib37]), and we therefore asked whether this EGF-like growth factor contributes to IL-33-induced IL-13 production. Using *Areg*^−/−^ mice, we found that IL-33 could not induce IL-13 expression and ERK activation in CD4^+^ T cells derived from the mLN of *H. polygyrus*-infected mice ([Figure 7](#fig7){ref-type="fig"}A and 7B), although EGFR expression on Th2 cells and the fraction of CD4^+^ T cells expressing the EGFR were similar in WT as in *Areg*^−/−^ mice ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Also, IL-33-induced IL-5 expression was unaffected ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Moreover, transfer of CD4^+^ T cells derived from *H. polygyrus*-infected *Areg*^−/−^ mice could not induce worm expulsion in MHC-II-deficient mice ([Figure 7](#fig7){ref-type="fig"}C), suggesting that Th2 cell-derived AREG contributes to worm expulsion in an autocrine fashion, enabling Th2 cells to function in an innate-like manner.Figure 7AREG Induces EGFR Phosphorylation at Tyr-992, which Allows for the Interaction between T1/ST2 and EGFRWT (gray) and *Areg*^*−/−*^ (purple) mice were infected with *H. polygyrus*, and on day 14 post infection, mLN were harvested.(A and B) mLN cells were stimulated with rIL-33, anti-CD3, or media, and the IL-13 (A) and p-ERK (B) expression was determined by intra-cellular staining and flow cytometry analysis.(C) MHCII-deficient mice were infected with *H. polygyrus* and 7 days post-infection received flow cytometry-sorted CD4^+^ T cells derived from mLN of naive or *H. polygyrus*-infected WT, *Egfr*^*fl/fl*^*xCd4-cre*, or *Areg*^*−/−*^ mice. Worm burden and egg counts were determined 2 weeks post infection.(D--F) mLN cells were stimulated with rIL-33, rAREG, both, or media only, and EGFR p-Y1068 (D), p-ERK (E), and IL-13 (F) expression was determined by flow cytometry analysis.(G) EGFR phosphorylation at position Y992 on CD4^+^ T cells derived from mLN of WT or *Areg*^*−/−*^*H. polygyrus*-infected mice in the presence or absence of rAREG.(H) HEK293T cells were transfected as indicated with T1/ST2 and the IL-1RacP in combination with WT EGFR or EGFR^Y992F^ mutant. Subsequently, the cell lysates were analyzed for the expression of the transfected proteins (input, left panel). The same lysates were also subjected to an EGFR-specific immunoprecipitation (EGFR-IP, right panel) or were treated with the isotype control (iso, right panel). Precipitates were analyzed by immunoblot.(I) mLN cells were stimulated with rIL-33 in the presence of monensin, and EGFR expression on CD4^+^ T cells was analyzed by flow cytometry.All data are representative of at least two independent experiments (mean ± SEM); results for individual mice are shown as dots. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Mechanistically, we found that in activated Th2 cells derived from *H. polygyrus*-infected *Areg*^−/−^ mice, IL-33 could only induce phosphorylation of Tyr-1068 of the EGFR in the presence of rAREG and thus ERK phosphorylation and IL-13 expression ([Figure 7](#fig7){ref-type="fig"}D--7F). Furthermore, in CD4^+^ T cells derived from *H. polygyrus*-infected WT mice, position Tyr-992 of the EGFR is constitutively phosphorylated, while this phosphorylation was missing in *Areg*^−/−^. Nevertheless, rAREG could restore this phosphorylation ([Figure 7](#fig7){ref-type="fig"}G). Co-expression and co-immunoprecipitation of an EGFR-Y992F mutant with T1/ST2 in HEK cells further demonstrated that activation via Tyr-992 of the EGFR is essential for the formation of a hetero-complex between T1/ST2 and the EGFR ([Figure 7](#fig7){ref-type="fig"}H). This finding was further supported by the fact that EGFR co-immunoprecipitation ([Figure S7](#mmc1){ref-type="supplementary-material"}D) and EGFR was co-internalized in the presence of monensin was enhanced in response to IL-33 treatment on CD4^+^ T cells derived from *H. polygyrus*-infected WT mice but not on CD4^+^ T cells derived from *H. polygyrus*-infected *Areg*^−/−^ mice ([Figure 7](#fig7){ref-type="fig"}I). Taken together, these data reveal that the AREG-induced Tyr-992 phosphorylation of the EGFR on Th2 cells allows for the formation of an active signaling complex between the EGFR and T1/ST2, essential for IL-33-induced IL-13 expression ([Figure S7](#mmc1){ref-type="supplementary-material"}E).

In conclusion, our data demonstrate that the innate-like effector function of Th2 cells at the site of infection is controlled by EGFR and AREG expression. In order to initiate their expression, Th2 cells require antigen-dependent activation, while their expression on activated Th2 cells is sustained by cytokine-induced signaling. In this way, TCR-mediated T cell activation controls the innate effector function of Th2 cells via EGFR expression.

Discussion {#sec3}
==========

Several groups have shown before that Th2 cells contribute to worm expulsion at the site of infection ([@bib2], [@bib13], [@bib35], [@bib37]). These findings raise the question of how Th2 cells are activated at the site of infection. A number of cell types, such as macrophages, endothelial cells, and ILC2, express MHC-II molecules and could therefore potentially present pathogen-derived antigens to Th2 cells. One well-established example for such an antigen-specific interaction at the site of infection is the MHC-II-mediated interaction between ILC2 and Th2 cells ([@bib28]). Nevertheless, antigen presentation at the site of infection is inherently less well organized than within the site-draining lymph nodes. In addition, a number of helminths not only fundamentally change protein expression during development but also have been shown to secrete products that directly interfere with antigen presentation ([@bib6]), suggesting that local immune escape mechanisms could limit the effectiveness of local antigen-based cytokine expression. The group of W. Paul demonstrated that Th2 cells, similar to ILC2, can function in an antigen-independent way, by secreting the effector cytokine IL-13 upon exposure to IL-33 ([@bib12]). IL-33 release, however, is found under a number of different inflammatory conditions. Thus, this TCR-independent way of cytokine expression by Th2 cells raised the question of how cytokine expression by Th2 cells might be controlled to prevent aberrant expression of IL-13, which can cause immune pathology and fibrosis ([@bib36]). Our data reveal an unexpected mechanism by which TCR-independent cytokine expression by Th2 cells is regulated. Th2 cells are primed and expand in a clonal, antigen-dependent manner. Once activated, Th2 cells upregulate EGFR expression and express AREG, which allows them to secrete the effector cytokine IL-13 following exposure to IL-33. Thus, in effect, via this EGFR-mediated licensing of Th2 cells, we observed a functional merger of the innate and adaptive immune responses at the site of infection in order to reach a sufficient mass at critical time points during infection. In this process, the involvement of antigen-specific Th2 cells allows for the rapid expansion of cells that can respond to infection independent of local antigen presentation, while at the same time these cells remain in their functional state closely controlled by antigen presentation, thereby assuring for optimal host resistance while preventing immunopathology.

Our finding that the interaction between T1/ST2 and the EGFR is further controlled by the type-2 cytokine and EGF-like growth factor AREG dovetails with our former findings demonstrating that AREG contributes to the efficient clearance of *Trichuris muris* infection ([@bib37]). In that publication, we showed that Th2-derived AREG contributed to helminth expulsion by enhancing the proliferation of the IEC layer at the site of infection. These findings appeared to be in conflict with the findings by the group of Richard Grencis, who had shown that the enhanced proliferation of the IEC layer was IL-13 induced ([@bib7]). Our current data now show that Th2 cell-expressed AREG in an autocrine fashion facilitates the IL-33-induced expression of IL-13 at the site of infection. Thus, it is tempting to speculate that also during *T. muris* infections, AREG may contribute to host resistance by licensing activated Th2 cells to express IL-13 at the site of infection in an IL-33-dependent way. This additional AREG-mediated control mechanism may further restrict the interaction of both receptors to Th2 cells.

Finally, our findings further emphasize the importance of signaling hetero-complexes between different cytokine receptor families for the functioning of the immune system. T1/ST2 has already been shown to form a signaling hetero-complex with c-kit, another RTK, on mast cells ([@bib8]). Thus, despite the fact that the molecular mechanism by which T1/ST2 interacts with these RTKs requires further, more detailed analysis, it appears that signaling hetero-complexes composed of trans-membrane receptors from different signaling families are a more common phenomenon and may add another, so far largely neglected layer of immune regulation. In particular, since the EGFR is expressed on a wide range of leukocytes and since our findings demonstrate that the EGFR can form hetero-complexes with other cytokine receptors to regulate their signal specificity, it is likely that the role of EGFR expression by leukocytes in the functioning of the immune system is underestimated to date. This notion is further supported by the observation that cancer patients treated with EGFR antagonists suffer not only from a wide range of side effects caused by loss of EGFR function on epithelial cells but also become more susceptible to infections ([@bib4]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat anti mouse CD4 (clone RM4-5)BiolegendCat\#100536Armenian Hamster anti mouse CD69 (clone H1.2F3)BiologendCat\#104528Anti mouse T1/ST2 (clone DJ8)MD BioproductsCat\#101001BRat anti mouse CD62L (clone MEL-14)BiolegendCat\#104424Rat anti CD44 (clone IM7)BiolegendCat\#103032Rat anti mouse CD45Rb (clone 16A)BD PharMingenCat\#553101Rat anti mouse CD25 (clone PC61)BiolegendCat\#102016Mouse anti mouse CD45.1 (clone A20)eBiosciencesCat\#17-0453-81Mouse anti mouse CD45.2 (clone 104)eBiosciencesCat\#12-0454-81Rat anti mouse CD8 (clone 53-6.7)BiolegendCat\#100706Rat anti mouse CD19 (clone 6D5)BiolegendCat\#115538Rat anti mouse SiglecF (clone E50-2440)BD PharMingenCat\#562681Rat anti mouse Ly6G (clone 1A8)BiolegendCat\#127628Rat anti mouse CD3 (clone 17A2)BiolegendCat\#100228Mouse anti mouse CD64 (clone X54-5/7.1)BiolegendCat\#139306Rat anti mouse Ly6C (clone HK1.4)BiolegendCat\#128024Armenian Hamster anti mouse CD11c (clone N418)BiolegendCat\#117334Rat anti CD11b (clone M1/70)BiolegendCat\#101241Rat anti mouse F4/80 (clone BM8)eBiosciencesCat\#25-4801-82Rat anti mouse MHCII (I-A/I-E) (clone M5/114.15.2)eBiosciencesCat\#47-5321-82Rat anti mouse CD90.2 (clone 30-H12)BiolegendCat\#105308Armenian Hamster anti mouse FcεR1 (clone MAR-1)BiolegendCat\#134309Mouse anti mouse NK-1.1 (clone PK136)BiolegendCat\#108710Mouse anti EGF-R (clone EGF-R1)AbcamCat\#Ab30Rat anti mouse IL-13 (clone eBio13A)eBiosciencesCat\#50-7133-80Rat anti mouse IL-4 (clone 11B11)BiolegendCat\#504104Rat anti IL-5 (clone TRFK5)BD PharMingenCat\#554395Rat anti mouse IFN-γ (clone XMG1.2)BiolegendCat\#505806Rabbit polyclonal anti p-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)Cell SignalingCat\#9101Mouse anti IκBα (clone L35A5)Cell SignalingCat\#4814Rabbit polyclonal anti p-EGFR (Tyr1068)Cell SignalingCat\# (D7A5) XP 3777Rabbit polyclonal anti p-EGFR (Tyr992)ThermoFisherCat\#44-786GRat anti FoxP3 (clone FJK-16 s)eBiosciencesCat\#50-5773-82Human anti GATA3 (clone REA174)Miltenyi BiotecCat\#130-108-061Mouse anti c-Maf (clone sym0F1)eBioscienceCat\#12-9855-41Rat anti mouse CD8 (clone 53-6.7)BioXcellCat\#BE0004-1Rat anti mouse B220 (clone RA3.3A1/6.1 (TIB-146))BioXcellCat\#BE0067Rat anti mouse CD11b (clone M1/70)BioXcellCat\#BE0007Rat anti mouse MHCII (I-A/I-E) (clone M5/114)BioXcellCat\#BE0108Armenian Hamster anti mouse CD3 (clone 145-2C11)BD PharMingenCat\#553058Rabbit polyclonal anti T1/ST2Thermo Scientific/PierceCat\#PA5-20077Rabbit polyclonal anti STAT6Cell SignalingCat\#9362Anti EGFR (clone EP38Y)AbcamCat\#ab52894Rabbit polyclonal hEGFRSanta Cruz BiotechnologyCat\#sc-03-GRabbit polyclonal anti SosCell SignalingCat\#5890Rabbit polyclonal anti SHP-2Cell SignalingCat\#3752Goat polyclonal anti hIL-33RR&D systemsCat\#Baf523Anti-hIL-1RacPR&D systemsCat\#AF676**Bacterial and Virus Strains***Heligmosomoides polygyrus*[@bib5]N/AMouse-adapted *Nippostrongylus brasiliensis*[@bib22]N/A**Chemicals, Peptides, and Recombinant Proteins**Brefeldin ASigmaCat\#B6542Recombinant mouse IL-13ImmunotoolsCat\#12340137Recombinant mouse IL-33PeproTechCat\#210-33Recombinant human HB-EGFR&D SystemsCat\#259-HERecombinant mouse IL-7PeproTechCat\#217-17Recombinant mouse IL-2BD BiosciencesCat\#550069Recombinant mouse TSLPeBiosciencesCat\#34-8498-82MEK inhibitorPromegaCat\#V1121GefitinibLC laboratoriesCat\#G-4408MarimastatAbcamCat\#Ab141276OVASigma-AldrichCat\#A5503**Critical Commercial Assays**LIVE/DEAD Fixable Blue Dead Cell Stain KitThermo FisherCat\#L23105Sheep anti-Rat IgG DynabeadsInvitrogenCat\#110.35IL-13 Mouse ELISA KiteBioscienceCat\#88-7137-76IL-5 Mouse ELISA KiteBioscienceCat\#88-7054-88**Deposited Data**Sequencing raw data of RNA-seq experimentGEO accession numberGEO: [GSE104096](ncbi-geo:GSE104096){#intref0010}**Experimental Models: Cell Lines**HEK293 cellsATCCN/AHaCaT cellsATCCN/A**Experimental Models: Organisms/Strains**EGFR^flox/flox^Natarajan A et al., 2007 PNAS 104:17081N/ACD4-CreTaconicsStock No: 4196FoxP3-CreThe Jackson LaboratoryStock No: 016959Areg^−/−^Luetteke NC et al., 1999 Development. 126:2739-50N/AMHCII^−/−\ (^B6;129S2-H2dlAb1-Ea/J)The Jackson LaboratoryStock No: 003374T1/ST2^−/−^Townsend MJ et al., 2000 J Exp Med. 191:1069N/AIL-13^−/−^[@bib20]N/A**Oligonucleotides**Primer for *Il13* mRNAApplied BiosystemsCat\#Mm00434204Primer for *Il5* mRNAApplied BiosystemsCat\#Mm00439646Primer for *Il4* mRNAApplied BiosystemsCat\#Mm00445259Primer for *Cd3e* mRNAApplied BiosystemsCat\#Mm00599684Primer for *Muc5ac* mRNAApplied BiosystemsCat\#Mm01276718Primer for *Areg* mRNAApplied BiosystemsCat\#Mm00437583Primer for *Rn18s* mRNAApplied BiosystemsCat\#Mm03928990**Recombinant DNA**pcDNA3-hIL-33RN/ApcDNA3-hIL-1RacPN/ApRK5-wt-hEGFRN/ApRK5-hY992F-EGFRN/A**Software and Algorithms**FlowJo 10FLOWJO, LLC<https://www.flowjo.com/>Prism 7GraphPad Software<https://www.graphpad.com/scientific-software/prism/>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and request for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dietmar Zaiss (<dietmar.zaiss@ed.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Breeding of experimental animals {#sec4.3.1}

C57BL/6J mice (*wt*, *Egfr*^*flox/flox*^, *Cd4-cre x Egfr*^*flox/flox*^, *Foxp3*-cre x *Egfr*^flox/flox^, *Areg*^−/−^ and MHCII-deficient *Aβ*^*−/−*^) were bred and maintained at the University of Edinburgh, Trinity College Dublin (T1/ST2-deficient *Il1rl1*^*−/−*^) or the Laboratory of Molecular Biology, Cambridge (*Il13*^−/−^) in specific-pathogen free conditions. Sex-matched mice were 6-8-weeks old at the start of the experiment, and all mice were housed in individually ventilated cages. Mice were not randomized in cages, but each cage was randomly assigned to a treatment group. Investigators were not blinded to mouse identity during necropsy but during worm and egg counts. Experiments were performed in accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986. All researchers were accredited by the UK government Home Office. Dispensation to carry out animal research at The University of Edinburgh was approved by the University of Edinburgh Animal Welfare and Ethical Review Body and granted by the UK government Home Office; as such all research was carried under the project licenses PPL70/8470 and 70/8483. All animal experiments in Ireland were performed under license in compliance with the Health Products Regulatory Authority and approved by the Trinity College Dublin's BioResources ethical review board. Note: Male and female mice were used to perform the experiments shown in this manuscript. However, none of the experiments were conducted using both sexes at the same time. We never observed an obvious difference between sexes within the parameters analyzed for our experiments.

Method Details {#sec4.4}
--------------

### Splenocyte cultures {#sec4.4.1}

Single cell suspensions of spleens were obtained by forcing the tissue through a 70 μM cell strainer. Subsequently, cells were treated with red blood cell lysis buffer (Sigma-Aldrich) and counted using an automated cellometer T4 (Peqlab, Radnor, PA). In some experiments, T helper cells were sorted based on CD3 and CD4 positivity and different T cell subpopulations were sorted as indicated. Cells were incubated in IMDM medium supplemented with 10% FCS, 1% l-glutamine, 1% penicillin/streptomycin and 5 × 10^−5^ M 2-mercaptoethanol at 37°C in a humidified atmosphere at 5% CO~2~.

### Cell Lines {#sec4.4.2}

HEK293 cells and HaCaT cells were cultured in IMDM medium supplemented with 10% FCS, 1% l-glutamine, 1% penicillin/streptomycin and 5 × 10^−5^ M 2-mercaptoethanol at 37°C in a humidified atmosphere at 5% CO~2~.

### Nematode infections, de-worming and IL-13 delivery {#sec4.4.3}

*H. polygyrus* and mouse-adapted *N. brasiliensis* were maintained by serial passage trough F1 (C57BL/6xCBA) and C57BL/6 mice respectively, as described previously ([@bib5], [@bib22]). Mice were infected by oral gavage with 200 *H. polygyrus* and subcutaneously with 250 *N. brasiliensis* third-stage larvae. For deworming, mice were treated orally with pyrantel embonate in the form of 2.5 mg Strongid P paste (Pfizer) in 0.2 mL water on day 14 post-primary infection ([@bib15]). In IL-13 delivery experiments, 5 μg of rmIL-13 (Immunotools) was injected intra-peritoneally at days 6, 7 and 8 post *H. polygyrus* infection. Egg output was analyzed in faeces and adult worm burdens were determined by removing the small intestine and exposing the lumen by dissection.

### *In vivo* delivery of Brefeldin A and duodena digestion {#sec4.4.4}

*In vivo* delivery of Brefeldin A was performed as previously described ([@bib18]). Briefly, Brefeldin A (Sigma) was resuspended at 20 mg/ml in DMSO. Further dilution to 1 mg/ml was made in PBS, and 250 μL were injected i.v.. 6 hours later duodena were harvested and intestial-resident leukocytes were purified by two sequantial pre-digestions (20 mins, at 37C) with HBSS containing: 10 mM HEPES, 5 mM EDTA, 1 mM DTT and 5% FCS in the presence or absence of Monensin (Invitrogen) (10 μM). After, samples were digested for 30 mins at 37C with HBSS containing 10 mM HEPES, 0.5 mg/mL Collagenase D, 0.5 mg/mL DNase I grade II, 3 mg/mL Dispase II (Roche) and 5% FCS. Single cell suspensions were prepared by forcing the samples through a 70-μm cell stainer and subsequent washes.

### Flow Cytometry and FACS-sorting {#sec4.4.5}

Cells were incubated with Fc block (CD16/CD32 and 10% mouse serum) and stained with a combination of the following commercial monoclonal fluorescently conjugated antibodies (clone, brand and catalog no. specified in the KEY RESOURCES TABLE): CD4, CD69, T1/ST2, CD62L, CD44, CD45Rb, CD25, CD45.1, CD45.2, CD8, CD19, SiglecF, Ly6G, CD3, CD64, Ly6C, CD11c, CD11b, F4/80, I-A/I-E (MHCII), CD90.2, FcεR1, NK-1.1 and EGF-R. For intracellular staining, cells were fixed with 2% paraformaldehyde in dPBS for 20 min at room temperature, permeabilized with 0.5% Saponin or ice-cold methanol then stained with IL-13, IL-4, IL-5, IFN-γ, p-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), IκBα, p-EGFR (Tyr1068), p-EGFR (Tyr992) or isotype control followed by anti-Rabbit IgG secondary antibodies (Invitrogen). For detection of FoxP3, GATA3 and c-Maf cells were stained for surface markers then fixed and permeabilized using FoxP3 staining buffer set (eBioscience). Cells were then stained with FoxP3, GATA3 and c-Maf for 30 min at room temperature. Live/Dead (Life Technologies) was used to exclude dead cells from analysis. Samples were analyzed by flow cytometry using Becton Dickinson FACS LSR II and FlowJo software. Alveolar macrophages were identified as described before ([@bib22]): lineage negative^--^ (CD19^--^, Ly6G^--^ and CD3^--^), CD64^+^, CD11c^+^ and SiglecF^+^. ILC2 cells were identified as described before ([@bib23]), detailed gating strategy is shown in [Figure S4](#mmc1){ref-type="supplementary-material"}E.

For some experiments, T cells from mLN of infected mice were enriched (as described below) and subsequently stained with a combination of antibodies to CD3, CD4, CD69, T1/ST2, CD62L, CD44, CD45Rb, CD25 and EGF-R prior to sorting on a FACS Aria (BD). T helper cells were sorted based on CD3 and CD4 positivity and different T cell subpopulations were sorted as indicated. T cell purity was verified by flow cytometry.

### RNA extraction and quantitative real-time PCR {#sec4.4.6}

Tissue was homogenized in TRIzol with a TissueLyser (QIAGEN) and RNA was isolated following manufacturer's instructions. Reverse transcription was performed using 1 μg of total RNA using 200 U of M-MLV reverse transcriptase, 10 mM dNTPs, and 0.5 μg Oligo dT15 and RNasin inhibitor (Promega). Expression of genes of interest was measured by real-time PCR with the Lightcycler 480 II system (Roche) using Taqman Master kit and specific primers (specified in the KEY RESOURCES TABLE), as previously described ([@bib21]). PCR amplification was analyzed using 2nd derivative maximum algorithm (LightCycler 480 Sw 1.5, Roche) and the expression of the gene of interest was normalized to the housekeeping gene *Rn18s*.

### T cell enrichment and adoptive transfer experiments {#sec4.4.7}

For transfer experiments, mLN were collected from donor mice 14 days after *H. polygyrus* infection. mLN single cell suspensions were prepared by forcing through a 70uM cell strainer and the homogenates were treated to lysate red blood cells. For transfer of CD4^+^ T cells, these cells were purified by negative selection using Sheep anti-Rat IgG Dynabeads (Invitrogen) and monoclonal antibodies (specified in the KEY RESOURCES TABLE) to CD8, B220, CD11b and I-A/I-E (MHCII) following manufacturer's protocol. Approximately 1.5 x10^6^ Cells were transferred intravenously. In some experiments, CD4^+^ T cell subpopulations were further purified by FACS-sorting prior to intra-venous transfer, in this case approximately 1 x10^5^ cells were transferred. All recipients received the same percentage of Th2 cells as determined by the analysis of GATA3 expression and/or IL-13 expression by re-stimulated CD4^+^ T cells. *H. polygyrus*-infected recipient mice received transferred cells on day 7 post-infection whereas *N. brasiliensis*-infected recipients mice received transferred cells at the same time of infection.

For the generation of resting T cells, donor mice were infected with *H. polygyrus* and two weeks after infection the mice were dewormed by oral deliver of pyrantel embonate in the form of 2.5 mg Strongid P paste in 0.2 mL water. After two weeks of deworming treatment mLNs were harvested and T cells were enriched as described above. Ova-specific activated and memory T cells were generated with nebulised ovalbumin. In brief, animals were immunized twice by an intra-peritoneal injection of 10ug of OVA (Sigma-Aldrich) dissolved in alum, with a break of two weeks between each immunization. Seven days following the second immunisation, mice were nebulised for 20 minutes on 5 consecutive days, with either PBS only, or with PBS containing 100ug/ml of ova, at a rate of 1 ml/minute. Thoracic lymph nodes (parathymic, posterior, mediastinal and paravertebral LN) were collected 24 h or 1 month following the last treatment to isolate activated or memory CD4^+^ T cells, respectively. T cells were FACS sorted and transferred as indicated with or without concomitant ip. delivery of ova/alum or adjuvant only.

### Th2 cells generation and RNaseq analysis {#sec4.4.8}

CD4^+^ CD25^−^ CD45Rb^hi^ cells were FACS-sorted from spleens of *wt* and EGFR^ΔCD4^ mice and cultured in IMDM medium supplemented with 10% FCS, 1% l-glutamine, 1% penicillin/streptomycin and 5 × 10^−5^ M 2-mercaptoethanol. Th2 cells were generated by adding IL-2 (1 ng/mL), IL-4 (2 ng/ml) and neutralizing IFN-γ antibody (clone R4.6A2, 5 μg/mL) into the culture. RNA was isolated using the RNeasy Mini Kit (QUIAGEN Cat. No. 74104). RNA seq data are deposited under GEO accession number: [GSE104096](ncbi-geo:GSE104096){#intref0030}.

### Immunoprecipitation on T cells {#sec4.4.9}

CD4^+^ T cells were enriched by negative selection using Sheep anti-Rat IgG Dynabeads as described above. Purified T cells were stimulated with IL-33 (PeproTech) (10 ng/mL) or vehicle for 1 hour. After culture, cells were lysed at 4°C for 30 min in 500 μL of lysis buffer containing: 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.05% Sodium azide and 1 mM phenylmethylsulfonyl fluoride (PMSF). The lysates were centrifuged at 10 000 × g for 10 min, and the supernatants were pre-cleared by adding protein A-Sepharose (50 μL) and incubated at 4°C for 1 hour, followed by centrifugation at 10 000 × g for 10 min. The pre-cleared supernatant was incubated with anti-T1/ST2 antibody (Thermo Scientific/Pierce, 10ug/ml) or control IgG at 4°C overnight, after which 50 μL of protein A-Sepharose was added for 4 h at 4°C with gentle rotation. The immune complexes were collected by centrifugation at 10 000 × g for 5 min at 4°C, washed three times with cold lysis buffer, and released by boiling with 5 × Laemmli loading buffer.

### Western blots {#sec4.4.10}

Cell lysates and samples from co-immunoprecipitation assays were resolved by 8% (m/v) SDS-PAGE in reducing conditions and transferred to nitrocellulose membranes. After blocking with 2% BSA, membranes were washed and incubated with an anti-Stat6, EGFR or T1/ST2 antibodies (brand and catalog no. specified in the KEY RESOURCES TABLE) overnight at 4°C. The membranes were washed and incubated with horseradish-peroxidase-labeled secondary antibodies for 1 hour at room temperature and exposed to ECL reagents.

### HEK293T transfection and immunoprecipitation {#sec4.4.11}

HEK293T cells (0.8 x10^6^ cells/sample) were seeded in DEMEM (Sigma) supplemented with 10% FCS but w/o antibiotics. Cells were incubated overnight (according to the lipofectamin transfection protocol). Cells were transfected with pcDNA3-hIL-33R, pcDNA3-hIL-1RacP, pRK5-wt-hEGFR or pRK5-hY992F-EGFR (1.3μg DNA/sample of each construct) (pRK5-wt-hEGFR and pRK5-hY992F-EGFR were kindly provided by Prof. Dr. F.-D. Böhmer; Department for Moleculare Cell biology, Jena) by using lipofectamin (Invitrogen) according to the manufacturer procedures. To obtain the same DNA content in every sample (total 4μg DNA/sample), single- and co-transfections were filled with empty vector (pcDNA3). Subsequently, HEK293T cells were incubated for 24h. Afterward, cells were lysed (with Lysis buffer containing: 20 mM HEPES, pH7.5; 10 mM EDTA; 40 mM β-glycerophosphate; 2,5 mM MgCl2; 2 mM orthovanadate; 1 mM dithiothreitol; 20 μg/ml aprotinin; 20 μg/ml leupeptin supplemented with 0,5% NP40). Protein concentration was determined by using the BCA-kit (Pierce). A small aliquot of every sample was taken to perform the input blot. Thereby, samples were treated and boiled in 6 x Laemmli buffer. Samples were analyzed by SDS-PAGE (8%) and western blotting by using the anti-hEGFR, the anti-Sos, the anti-Shp2, the anti-hIL-33R and the anti-hIL-1RacP antibodies (brand and catalog no. specified in the KEY RESOURCES TABLE). The rest of the samples were subjected to anti-hEGFR-specific or to an isotype (as non-specific goat control immunoglobulins; Gentaur) immunprecipitation overnight. Samples were treated with Protein-G sepharoses (invtrogen) for 4-6h. Precipitates were washed with Lysisbuffer and PBS, and were treated and boiled in 6 x Laemmli buffer. Immunoprecipitated samples were analyzed by SDS-PAGE (8%) and western blotting by using anti-hEGFR, anti-Sos, anti-Shp2, anti-hIL-33R and anti-hIL-1RacP antibodies. As secondary antibodies for all western blots we used anti-rabbit-POD (for the detection of hEGFR, Sos, Shp2 and hIL-1Racp) (Santa Cruz Biotechnology). For detection of the hIL-33R we a used anti-goat-POD (Santa Cruz Biotechnology) or POD-coupled streptavidine (Roche). Membranes were developed with the ECL-reagent (Pierce).

### Cytokine and *H. polygyrus* antigen ELISA {#sec4.4.12}

Mouse IL-13 and IL-5 were measured according to manufacturers instructions using ELISA Kits (eBioscience). *H. polygyrus* antigen (HEX; [@bib10]) was prepared by homogenizing adult worms in PBS, which was centrifuged (13 000 × g, 10 min); the supernatant was filtered (0.2 μm) and stored at 1.5 mg/mL at --80°C. Antigen-specific antibody responses were determined by ELISA as described before ([@bib10]). Multisorp (Nunc) plates were coated with 5 μg/mL *H. polygyrus* antigen in 0.06 M carbonate buffer pH 9.6, overnight at 4°C. Plates were blocked with 5% BSA for 2 h at 37°C. Faecal homogenates and sera were diluted in TBS/0.05% Tween and added to wells overnight at 4°C. Antigen-specific Ig isotypes were detected with HRP-conjugated detecting antibodies (Southern Biotechnology), with TMB peroxidase substrate.

### *Ex vivo* re-stimulation conditions {#sec4.4.13}

To determine the induction of cytokines expression, FACS-sorted T cells and mLN cells or splenocytes were cultured in 96-well plates in IMDM medium, 10% FCS, 1% l-glutamine, 1% penicillin/streptomycin (GIBCO), 5 × 10^−5^ M 2-mercaptoethanol in the presence or absence of Monoensin (Invitrogen) (10 μM) and rmIL-33 (PeproTech) (10 ng/mL) or anti-CD3 (BD, 145-2C11) (2 μg/mL) for six hours. Alternatively, intracellular amounts of p-EGFR (Y1068 and Y992), p-ERK and IκBα were analyzed after 30 minutes of stimulation with IL-33 (10 ng/mL), anti-CD3 (2 μg/mL), AREG (R&D) (10 ng/mL) or HB-EGF (R&D) (10 ng/mL). To analyze EGFR or AREG induction, splenocytes or FACS-sorted T cells were re-stimulated overnight with *H. polygyrus* excretory-secretory products (HES; [@bib16]) (1 μg/mL), adult worm extract (HEX) (10 μg/mL), anti-CD3 (2 μg/mL), IL-7 (PeproTech) (20 ng/mL), IL-2 (BD) (1 ng/mL), TSLP (eBiosciences) (20 ng/mL) and IL-33 (10 ng/mL). Inhibitors were used at the following concentrations: MEK inhibitor (Promega)(10 μM), Gefitinib (LC laboratories) (1 μM) and Marimastat (AbCam) (25 μM). The inhibitory effect of Marimastat (25 μM) was checked by its ability to prevent the release of activated Amphiregulin by transfected HEK cells. Under these conditions cell viability was higher than 90% as compared to 97% at the start of the experiment.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Normal distribution of data was determined by visual examination of residuals. Statistical evaluation of different groups was performed either by analysis of variance (ANOVA) followed by the Turkey multiple comparison test or by non-parametric Mann-Whitney test, as indicated. An α threshold ≤ 5% (p ≤ 0.05) was considered significant. All statistical calculations were performed using PRISM, (Graphpad, La Jolla, CA).

Data and Software Availability {#sec4.6}
------------------------------

The accession number for the RNA-seq dataset reported in this paper is GEO: [GSE104096](ncbi-geo:GSE104096){#intref0035}.
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